الولايات المتحدة · منصات وبيانات · The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

نشره The Motley Fool · الولايات المتحدة منذ 2 س

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

اقرأ المقال كاملًا على The Motley Fool سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.fool.com)

يستحق القراءة أيضًا

MarketBeat

Satellogic Targets Daily Global Intelligence With Merlin Satellite Constellation

Seeking Alpha

Fusion Fuel Green deal cuts QIND’s Al Shola Gas payments due to $7M

MarketWatch

Markets are pricing in long-term AI winners. This veteran investor says history proves customers win more than innovators.

Benzinga

Best Tech Stocks Right Now

Investing.com

Cantor Fitzgerald reiterates Texas Instruments stock neutral rating

Yahoo Finance